Site Map sitemap   |  Login login



01/02/2016 TeraCrystal, a Romanian-Finnish solid state characterization company, assisted Icon Bioscience, Inc, a USA based ocular delivery company, in characterization of their proprietary Verisome™ delivery platform. The technical data package generated by TeraCrystal’s state-of-the art in situ characterization methodologies successfully support the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The project was completed in collaboration with the US based consulting firm, Bryla CMC-Reg Consulting, LLC.

23/05/2016 TeraCrystal will attend The 15th European Powder Diffraction Conference (EPDIC15), held in Bari, from 12 to 15 June 2016. The representatives from TeraCrystal will be presenting the following topic” Powder diffraction as tool for identification of isomorphous solvates” showcasing our latest research in solid state characterization of active pharmaceutical ingredients.

To arrange a meeting with us at the event, please contact us at .

15/05/2016 TeraCrystal is pleased to announce that Leif Hilden, President and Mihaela Pop, Chief Scientific Officer will be attending and presenting at the upcoming 7th Nordic Process Chemistry Forum which will take place between May 25th/27th in Copenhagen and in the city of Helsingør. At the conference, representatives from TeraCrystal will be showcasing some of the company's latest research in enabling technology development for preclinical applications.

05/05/2016 As a part of CORE consortium, TeraCrystal has been awarded a Horizon 2020 grant (MSCA-ITN) with the primary objective of delivering highly trained multidisciplinary experts in the field of Crystallization-based Continuous Resolution.

The CORE program (Continuous Resolution and Deracemization of Chiral Compounds by Crystallization) is a four-year European Training Network (ETN) project which is coordinated by University of Strathclyde (Professor Joop H. ter Horst). The consortium brings together complementary partners, including 8 academic institutions from 6 countries, four small medium sized enterprises and a large industrial partner from pharmaceutical industry.

20/10/2015 TeraCrystal is proud to announce the formation of its advisory board with visionary leaders, Adrian Bot and Piotr Bryla. We look forward to continuing to growth with the help of this accomplished frontrunners from the worlds of industry, research, development and public policy.

07/09/2015 TeraCrystal will be attending CPhI 2015 in Madrid and will be glad to meet people interested in how TC can solve the most complex solid state chemistry issues. Our scientists will explain how we have integrated advanced analytical techniques (i.e XPS, TEM, SS-NMR, molecular modelling and SC-XRD) to our services, being able to offer complete solutions leading to a rapid, risk-reduced and cost efficient progression of drug candidates through development and commercialization. We invite you to meet us at the booth 3H106 and to schedule a meeting at

01/09/2015 TeraCrystal is pleased to announce that we have entered into a research collaboration with NanoMEGAS., focused on the development and commercialization of novel and advanced analytical services for pharmaceutical industry.

01/06/2015 TeraCrystal and Oy Innohill Finland announced that they have entered into an agreement under which, Innohill becomes shareholder of TeraCrystal. This partnership, which combines two highly complementary proficiencies, will create significant value for the customers, both companies having a sharp focus on delivering superior value to clients. It will also serve to accelerate their strategic plans, enabling them to deliver more complete solutions to the pharmaceutical industry.

15/04/2015 Dr. Mihaela Pop, Chief Scientific Officer at TeraCrystal will be guest speaker, at two days course entitled “Modern Approach of Pharmaceutical Solids Formulation & Process Development” organized by proGamma Science Corporation, which will take place at Formulation Event on May 21-22, 2015 in Montreal, Canada. This course covers topics related to pharmaceutical preformulation, crystal engineering, formulation and manufacturing process development, scale up and optimization strategies. Dr. Pop's presentation will focus on solid state research and its importance and application to the pharmaceutical industry. Attached flyer provides conference details and registration form.

01/03/2015 TeraCrystal, a dynamic contract research organization (CRO) providing the pharmaceutical industry with “solid state“ chemical development services announces the collaboration agreement with Bryla CMC-RegConsulting LLC, specialized in global CMC and CMC Regulatory Affair solutions. The business activities and services of both companies are complementary and will be able to offer Customers integrated solutions leading to a rapid, risk-reduced and cost efficient progression of drug candidates through development and commercialization processes. Read more ...

Contact us: tel/fax: +4(0)364.439.995